CTI commences Pixantrone trial
The trial is expected to compare a blend of Pixantrone plus Rituximab to a combination of Gemcitabine plus Rituximab in patients with relapsed or refractory DLBCL who have
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
The cellulosic food solutions which Ashland Aqualon Functional Ingredients is going to launch include Benecel methylcellulose, hydroxypropylmethylcellulose, Bondwell cellulose gum, Aquasorb cellulose gum (CMC), Klucel and AeroWhip hydroxypropylcellulose